ERYTHROPOIETINS IN ANAEMIA TREATMENT OF CHRONIC RENAL FAILURE (CRF) INDIVIDUALS: HOW DO WE PRESCRIBE THEM?
The present investigation presents integrated data on selection criteria for erythropoietin drugs set forth by doctors, health care surgeon-generals and patients for the treatment of anaemic syndrome in chronic renal failure patients. A number of substantial differences in the erythropoietin selection approaches applied by practicing doctors and health care surgeon-generals have been revealed. It has been established that hardly any pharmacoeconomic peculiarities of erythropoietin are taken into account in the decision process. The vast majority of prescription cases show lack of reference to the patients body mass or regard to the requirements to the dose titration regimens in anaemia compensation strategies.